March 14, 2009Introducing new international blog to discuss issues relevant to human tumor assays:  First post  considers an excellent article in the current issue of Internal Medicine News, relating to an emerging controversy over the regulation of cancer tests.

February 19, 20095FU activity in MTT assay predicts for long-term patient survival in metastatic colorectal cancer. Presentation at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium January 17, 2009. Click here for slide presentation on ASCO website.

September 10, 2008Lapatinib enhances the antivascular activity of bevacizumab and has superior antivascular activity compared to sorafenib. Presentation at the American Society of Clinical Oncology Breast Cancer Symposium September 5, 2008. Click here for slide presentation on ASCO website.

August 10, 2008New method reported for testing anti-angiogenic/anti-microvascular agents, such as bevacizumab (Avastin) and for testing for synergy between different anti-microvascular agents on an individual patient, individual tumor basis. Click here for technology example.

An article appearing today in the Journal of Internal Medicine reports the discovery of the first practical laboratory test to guide the use of new-generation drugs that kill cancer cells by cutting off their blood supply. The new test was developed at the Weisenthal Cancer Group in Huntington Beach, CA, and is called the Microvessel Viability (MVV) Assay.  It identifies the activity of both single drugs and also combinations of drugs in human cancer at the level of individual patients and individual cancers.  It works by measuring drug effects upon endothelial cells which make up blood vessels. Use of the test has the potential to identify new cancer treatments, prolong lives, save money, and spare patients exposure to harmful side-effects of ineffective treatments.  The MVV test is also a powerful development tool which can identify effective new drug combinations, potentially streamlining new drug development and leading to new and better treatments for cancer patients.  It is probable that major advances will come from the use of anti-blood vessel drugs in combination, analogous to the treatment of HIV/AIDS.  A major problem to date has been the lack of a relevant and practical system for testing anti-microvascular drugs against human tumors in which to discover synergistic anti-microvascular drug combinations. The MVV test is both relevant and practical for use in discovering synergistic drug combinations and identifying which patients are most likely to benefit from which drug combinations. (Weisenthal, LM, Patel, N, and Rueff-Weisenthal, C. Cell culture detection of microvascular cell death in clinical specimens of human neoplasms and peripheral blood. J Intern Med 264:275-287, September 2008).

doi: 10.1111/j.1365-2796.2008.01955.x

Link to ongoing blog discussion/debate concerning the MVV Assay in particular and cell culture testing in general.